General Characteristics of Patients, Tumor, Immunotherapy, and 18F-FDG PET/CT Studies
| Parameter | Characteristic | Data |
|---|---|---|
| Age (y) | 65.8 ± 16.1 | |
| Sex | Male | 45 (63) |
| Female | 27 (38) | |
| Subtype | Adenocarcinoma | 43 (60) |
| Squamous cell carcinoma | 21 (29) | |
| Large cell carcinoma | 7 (10) | |
| NA | 1 (1) | |
| Stage | I | 1 (1) |
| II | 9 (13) | |
| III | 23 (32) | |
| IV | 29 (40) | |
| NA | 10 (14) | |
| PD-1 inhibitor | Nivolumab | 62 (86) |
| Pembrolizumab | 10 (14) | |
| ICI cycles between 2 PET studies | 2–8 (median, 4) | |
| Time from baseline PET/CT to first ICI (d) | 21.5 ± 20.7 | |
| Time from last ICI to follow-up PET/CT (d) | 17 ± 8.19 | |
| 18F-FDG dose (MBq) | Baseline PET/CT | 273.8 ± 32.9 |
| Follow-up PET/CT | 266.1 ± 36.2 | |
| P = 0.01 | ||
| Uptake time (min) | Baseline PET/CT | 68.0 ± 9.2 |
| Follow-up PET/CT | 68.1 ± 10.0 | |
| P = 0.96 | ||
| Blood sugar (mmol/L) | Baseline PET/CT | 6.2 ± 1.4 |
| Follow-up PET/CT | 6.3 ± 1.5 | |
| P = 0.43 | ||
| Liver SULpeak (mean) | Baseline PET/CT | 1.7 ± 0.2 |
| Follow-up PET/CT | 1.7 ± 0.2 | |
| P = 0.25 |
NA = not available.
Qualitative data are number followed by percentage (n = 72); continuous data are mean ± SD.